BIIB News 314.76 06/26/2014 04:31:25 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 314.76 $BIIB

Isis Pharma Gets $1M Milestone Payment from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 5:10PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $1 million milestone payment from GlaxoSmithKline pertaining to the advancement of ISIS-TTR in phase II/III study.

Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 3:30PM CDT
Ligand Pharmaceuticals Inc. (LGND) inked a deal with TG Therapeutics, Inc. to develop and commercialize Ligand's IRAK-4 inhibitors.

British Columbia to Reimburse TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis
CNW Group - Wed Jun 25, 10:00AM CDT
Biogen Idec Canada announces today that TECFIDERATM (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1)

Critical Alerts For Vertex Pharmaceuticals, Dollar Tree, Avis, Ryder, and Biogen Released By InvestorsObserver
PR Newswire - Wed Jun 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRTX, DLTR, CAR, R, and BIIB.

XenoPort's XP23829 in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:52PM CDT
XenoPort, Inc. (XNPT) has commenced a phase II study on XP23829 for moderate-to-severe chronic plaque-type psoriasis.

Insider Trading Alert - BIIB, FDS And GCO Traded By Insiders
at The Street - Tue Jun 24, 9:45AM CDT
Stocks with insider trader activity include BIIB, FDS and GCO

Stocks with Upgraded Broker Ratings - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jun 24, 3:05AM CDT
Stocks with Upgraded Broker Ratings - Screen of the Week

AbbVie, Shire Give Bullish Guidance Amid Buyout Talk
at Investor's Business Daily - Mon Jun 23, 10:24AM CDT
Big pharma AbbVie (ABBV) raised its 2014 earnings guidance Monday, sending the company's stock up 1.5% in morning trading on the stock market. Meanwhile, AbbVie's buyout target Shire (SHPG) detailed its own bullish guidance in explaining to investors...

Trade-Ideas: Biogen Idec (BIIB) Is Today's Momo Momentum Stock
at The Street - Fri Jun 20, 9:32AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate

Global Human Papillomavirus Infections Pipeline Analysis 2014
M2 - Thu Jun 19, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r42gfc/human) has announced the addition of the "Human Papillomavirus Infections Pipeline Analysis" report to their offering. Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an ideal vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way. The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines. Human Papillomavirus Infections Vaccine Pipeline Analysis - Report Highlights: - Human Papillomavirus Vaccine Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug Clinical Development Phase: 47 - Suspended & Discontinued Drug Profiles: 46 - Competitive Landscape Companies Mentioned - Advanced Viral Research - BioSphings, - Biogen Idec, - EyeGene, - Helix BioPharma, - Inviragen, - MedImmune, - Merck & Co, - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r42gfc/human

Is This the Next Blockbuster MS Treatment?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Wed Jun 18, 4:30PM CDT
Biogen Idec   and its partner AbbVie reported good late stage results for multiple sclerosis drug daclizumab. While some are concerned about the increase in serious infections and a higher relapse rate than its earlier study, it shouldn't stop the...

Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 4:03PM CDT
Biogen Idec (BIIB) and partner AbbVie (ABBV) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab.

Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs.

Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Tue Jun 17, 3:55PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $302.01 to a high of $307.46. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $306.40 on volume of 857,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.03%
Comtex SmarTrend(R) - Tue Jun 17, 3:55PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $302.01 to a high of $307.46. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $306.40 on volume of 857,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

2 Exciting Developments for Biogen Idec Inc.
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 17, 8:02AM CDT
Biogen , which just got nod from the FDA for its potential blockbuster hemophilia drug Eloctate last week, has also now cleared a major hurdle for a drug in its multiple sclerosis franchise. Joint developers Biogen and AbbVie announced Monday...

True North Therapeutics Announces $22 Million Series A Financing
Business Wire - Tue Jun 17, 6:00AM CDT
True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, announced today that it has completed a $22 million Series A equity financing. Proceeds from the financing will be used to advance True North's lead drug candidate, TNT009, into clinical development, with the initiation of the first human clinical trial planned for early 2015. The total Series A round encompasses initial funds from the spin-out of True North Therapeutics from iPierian, Inc., announced in September 2013. Investors in the Series A financing include Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures, and Baxter Ventures.

Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec
PR Newswire - Tue Jun 17, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under Isis' and Biogen Idec's 2013 strategic collaboration to advance the treatment of neurological disorders. This collaboration combines Biogen Idec's expertise in neurology with Isis' leadership in antisense technology to develop novel therapies to treat neurological disorders and is the fourth collaboration between the two companies.

Our Drug Works! But There's a Catch ...
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 16, 5:21PM CDT
AFFiRiS' press release read like a monumental scientific discovery: Breakthrough in Alzheimer's disease: AFFiRiS halted clinical progression in Alzheimer patients upon treatment with AD04 in a phase II clinical study There's just one catch:...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bill Targets 15% Federal Goal for Women-Owned Firms

Updated Category News Views 28

Federal procurement has a stubborn habit of sounding abstract until you remember that contracts can decide whether a small company hires, invests, or simply keeps the lights on. Senator Adam Schiff introduced the Women's Economic Fairness and Small Business Contracting Act on November 19, 2026, proposing to raise the federal goal for Women-Owned Small Businesses from 5%...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 110

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 0

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 51

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 150

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes

Updated Category News Views 118

A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 55

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 17

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading

Top 5 Most Recently Viewed Articles

Addgene Launches Innovative Antibody Characterization Platform

Updated Category News Views 109

Addgene Launches Innovative Antibody Characterization Platform Addgene, a visionary organization dedicated to enhancing scientific research, recently introduced a groundbreaking antibody characterization platform that draws from its extensive antibody catalog. This initiative aims to significantly advance the field of biomedical research by ensuring that antibodies are...

Continue Reading
Nishant Saxena Joins Jeune Aesthetics as CFO to Drive Growth

Updated Category News Views 294

Jeune Aesthetics Welcomes New Chief Financial Officer Jeune Aesthetics has taken a significant step forward by appointing Nishant Saxena as its Chief Financial Officer (CFO). This decision comes at a crucial time as the company prepares to advance its growth strategies and innovate in the field of medical aesthetics designed to combat aging skin. Understanding the...

Continue Reading
Organ Preservation Solutions Market to Reach $512.62 Million by 2031

Updated Category News Views 144

Growth of the Organ Preservation Solutions Market The organ preservation solutions market is experiencing significant growth as the global demand for organ transplantation rises. According to a comprehensive report from The Insight Partners, it is projected that this market will reach a remarkable $512.62 million by 2031 with a compound annual growth rate (CAGR) of 8.1%....

Continue Reading
Alpine Income Property Trust Secures $14.1 Million Mortgage Loan

Updated Category News Views 133

Alpine Income Property Trust Makes Strategic Mortgage Investment WINTER PARK, Fla. – Alpine Income Property Trust, Inc. (NYSE: PINE), a well-known real estate investment trust, has recently announced a significant investment by originating a first mortgage loan. The loan investment, amounting to $14.1 million, is secured by a luxury residential development featuring...

Continue Reading
Zenity Introduces New Framework for Securing GenAI Systems

Updated Category News Views 127

Zenity Introduces GenAI Attacks Matrix for Enhanced Security Zenity, a leader in the security domain for enterprise copilots and low-code development, has launched its innovative security framework known as the GenAI Attacks Matrix. This open-source initiative is inspired by the renowned MITRE ATLAS and developed with contributions from top security researchers worldwide,...

Continue Reading